Survival Outcomes and Prognostic Factors in Rheumatoid Arthritis Patients Receiving Biologic or Targeted Synthetic Therapy: Real-World Data.

However, in the survival follow-up, no significant difference in therapeutic modality was found according to the type of b/tsDMARDs, and other treatment methods and comorbidities did not reach statistical significance ( Table 2 and Table 3 ). 3.3.

also in 111,027 other papers